Roche's latest big bet in exploring and discovering the next generation of cancer immunotherapies rests on a large deal with Adaptive Biotechnologies Corp. to develop T-cell receptor (TCR) therapies tailored for each individual patient.
Roche and Adaptive announced a development and commercialization deal on Jan. 4, right before the J.P. Morgan Healthcare Conference kicked off in San Francisco
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?